We are live on
!
Find out more
FCM
Farallon Capital Management Portfolio holdings
AUM
$17.5B
1-Year Est. Return
50.95%
This Fund
S&P 500
This Quarter
Est. Return
+26.99%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$12.5B
AUM Growth
+$844M
(+7.2%)
Cap. Flow
-$1.62B
Cap. Flow
% of AUM
-12.95%
Top 10 Holdings %
Top 10 Hldgs %
33.14%
Holding
137
New
32
Increased
25
Reduced
37
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
T-Mobile US
TMUS
|
+$331M |
| 2 |
Aon
AON
|
+$321M |
| 3 |
WUBA
58.com Inc
WUBA
|
+$256M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$217M |
| 5 |
TIF
Tiffany & Co.
TIF
|
+$191M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$1.65B |
| 2 |
Cigna
CI
|
+$142M |
| 3 |
Fidelity National Information Services
FIS
|
+$135M |
| 4 |
General Dynamics
GD
|
+$132M |
| 5 |
Wabtec
WAB
|
+$113M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 42.53% |
| 2 | Communication Services | 18.4% |
| 3 | Technology | 10.42% |
| 4 | Financials | 7.52% |
| 5 | Industrials | 3.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
PUT
iShares China Large-Cap ETF
FXI
$4.31B
| $22.3M | 0.18% |
+562,500
| New | +$21.9M |
|
77
Veracyte
VCYT
$3.8B
| $22M | 0.18% |
850,000
-525,000
| -38% | -$13.1M |
|
|
AMRN
78
Amarin Corp
AMRN
$303M
| $21.6M | 0.17% |
156,250
-25,000
| -14% | -$3.44M |
|
|
NVTA
79
DELISTED
Invitae Corporation
NVTA
| $19.9M | 0.16% |
656,528
-1,218,772
| -65% | -$21.3M |
|
80
Zymeworks
ZYME
$1.67B
| $19.8M | 0.16% |
550,000
-1,200,000
| -69% | -$44.2M |
|
81
Howmet Aerospace
HWM
$112B
| $19M | 0.15% |
+1,199,186
| New | +$15.8M |
|
82
Krystal Biotech
KRYS
$9.66B
| $18.6M | 0.15% |
450,000
+200,000
| +80% | +$9.62M |
|
|
PRNB
83
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
| $17.9M | 0.14% |
300,000
-84,674
| -22% | -$5.23M |
|
|
ZEAL
84
DELISTED
Zealand Pharma A/S American Depositary Shares
ZEAL
| $17.5M | 0.14% |
500,000
-250,000
| -33% | -$8.89M |
|
85
Liquidia Corp
LQDA
$8.02B
| $15.6M | 0.12% |
+1,850,000
| New | +$14M |
|
|
TCDA
86
DELISTED
Tricida, Inc. Common Stock
TCDA
| $13.7M | 0.11% |
500,000
-500,000
| -50% | -$13.6M |
|
87
uniQure
QURE
$3.22B
| $13.5M | 0.11% |
300,000
+50,000
| +20% | +$2.95M |
|
88
Royalty Pharma
RPRX
$25.3B
| $13.4M | 0.11% |
+275,000
| New | +$13.6M |
|
|
RC
89
Ready Capital
RC
$308M
| $11.7M | 0.09% |
1,350,226
+82,330
| +6% | +$560K |
|
90
Savara
SVRA
$1.19B
| $11.1M | 0.09% |
4,470,964
-354,122
| -7% | -$862K |
|
91
CRISPR Therapeutics
CRSP
$5.17B
| $11M | 0.09% |
150,000
-200,000
| -57% | -$11.7M |
|
|
CNST
92
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $10.5M | 0.08% |
+350,000
| New | +$12.6M |
|
93
Pacific Biosciences
PACB
$370M
| $10.3M | 0.08% |
3,000,000
| – | – |
|
94
Akebia Therapeutics
AKBA
$252M
| $10.2M | 0.08% |
750,000
-500,000
| -40% | -$5.17M |
|
|
ATTO
95
DELISTED
Atento S.A.
ATTO
| $7.71M | 0.06% |
+2,230,357
| New | +$11.7M |
|
|
AKUS
96
DELISTED
Akouos Inc
AKUS
| $5.06M | 0.04% |
+225,000
| New | +$5.02M |
|
|
AMTI
97
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
| $5.03M | 0.04% |
+200,000
| New | +$5.05M |
|
|
RPTX
98
DELISTED
Repare Therapeutics
RPTX
| $4.65M | 0.04% |
+150,000
| New | +$4.82M |
|
|
ARYBU
99
DELISTED
ARYA Sciences Acquisition Corp II Unit
ARYBU
| $4.64M | 0.04% |
+400,000
| New | +$4.4M |
|
|
FUSN
100
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $4.37M | 0.04% |
+250,000
| New | +$4.35M |
|
Similar funds
BBA
MCM
LA
CM
ASRS
PP
VMPIC
HNB
Farallon Capital Management's Q2 2020 Portfolio in Review
As of Q2 2020, Farallon Capital Management held 137 positions worth $12.5B, up 7.2% from $11.7B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Farallon Capital Management withdrew a net $1.62B in Q2 2020, closing 18 positions and reducing 37 holdings. Its most notable exit was Allergan plc, an estimated $1.65B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 43% of assets, down from 52% a quarter earlier, followed by Communication Services and Technology.
Against the trend, Farallon Capital Management opened a new position in T-Mobile US worth $360M.
- Farallon Capital Management's largest Q2 2020 buy was T-Mobile US: 3,457,631 shares worth $360M.
- Farallon Capital Management added most to Blackstone in Q2 2020, an estimated $125M increase.
- Farallon Capital Management's biggest Q2 2020 reduction was Cigna, cutting an estimated $142M.
- Farallon Capital Management fully exited Allergan plc in Q2 2020, selling an estimated $1.65B.
- Farallon Capital Management's ten largest holdings make up 33% of its $12.5B portfolio in Q2 2020.
- Farallon Capital Management opened 32 new positions and closed 18 in Q2 2020.
- Farallon Capital Management's portfolio value rose 7.2% quarter-over-quarter to $12.5B.
Based on Farallon Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.